Second-generation BTK inhibitors show reduced heart-related side effects compared to first-generation inhibitors in B-cell blood cancer patients. Atrial fibrillation occurred in 15.65% of ...

BTK inhibitors have transformed B-cell malignancy treatment, with distinct resistance mechanisms linked to specific inhibitors. Covalent inhibitors often lead to BTK C481 mutations, while non-covalent ...

We thank Gang Lv and colleagues for the response to our study.1 We agree that minimal residual disease (MRD) monitoring could help to optimise the treatment of mantle-cell lymphoma with ibrutinib and ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...

• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference ...